La cadena de opciones muestra datos clave de las opciones de acciones de Cardlytics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cardlytics..

Cardlytics (NASDAQ:CDLX) Bolsa, Cadena de Opciones

Cardlytics

Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.

Cardlytics Inc

CARDLYTICS ORD

Canaccord Genuity analyst Maria Ripps maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Hold and raises the price target from $56 to $64.

News

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Zillow Gr, Raises Price Target to $64

Canaccord Genuity analyst George Gianarikas maintains Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) with a Buy and lowers the price target from $25 to $18.

WOLF

Canaccord Genuity Maintains Buy on Wolfspeed, Lowers Price Target to $18

Canaccord Genuity analyst George Gianarikas maintains Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>) with a Buy and lowers the price target from $3.25 to $1.5.

Canaccord Genuity Maintains Buy on Wallbox, Lowers Price Target to $1.5

Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock is trading higher on Thursday after the company reported better-than-expected third-quarter financial results and raised its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41786284/gilead-sciences-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">fiscal year 2024 guidance</a>.
On Wednesday after market, Gilead reported third-quarter adjusted EPS of $2.02, down from $2.29 a year ago, beating the consensus of $1.55.
The HIV drug maker reported sales of $7.55 billion, up 7% year over year, beating the consensus of $7 billion, primarily due to higher sales in HIV and Veklury&nbsp;(remdesivir), Oncology and Liver Disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41434127/gilead-sciencesmercks-investigational-once-weekly-hiv-combo-therapy-shows-sustained-virus-suppres" rel="noreferrer noopener">Gilead Sciences/Merck&#8217;s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks</a>
HIV&nbsp;product sales increased 9% to $5.1 billion, with Biktarvy sales increased 13% to $3.5 billion. Descovy&nbsp;sales jumped 15% to $586 million.
The&nbsp;Liver Disease&nbsp;portfolio sales increased 4% to $733 million. Veklury&nbsp;sales increased 9% to $692 million.
&#8220;Gilead&#8217;s third-quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy,&#8221; said Daniel O&#8217;Day, Chairman and CEO.
Guidance: Gilead Sciences raised its fiscal year 2024 adjusted EPS guidance from $3.60 &#8211; $3.90 to $4.25 &#8211; $4.45 compared to the consensus of $3.81.
The company expects 2024 product sales of $27.8 billion &#8211; $28.1 billion compared to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40291958/analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-" rel="noreferrer noopener">prior guidance of</a> $27.1 billion &#8211; $27.5 billion.
Analysts&#8217; reaction:
<ul>
<li>Piper Sandler maintains Gilead Sciences with an Overweight, raising the price <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $95 to $105</a>.</li>
<li>Barclays reaffirms Gilead with an Equal-Weight rating while boosting the price target from $84 to $95.</li>
<li>Wells Fargo maintains Gilead with an Overweight rating, raising the price target from $100 to $105.</li>
<li>Cantor Fitzgerald reiterates Gilead with a Neutral rating, increasing the price target from $70 to $80.</li>
<li>Goldman Sachs maintains Gilead&#8217;s Neutral rating, lifting the price target from $74 to $84.</li>
<li>RBC Capital maintains Gilead&#8217;s Sector Perform rating and boosts the price target from $75 to $81.</li>
<li>JP Morgan maintains Gilead with an Overweight rating, raising the price target from $100 to $105.</li>
<li>Baird maintains Gilead&#8217;s Neutral rating, increasing the price target from $80 to $95.</li>
</ul>
Price Action: GILD stock is up 5.94% at $97.14 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales</a></li>
</ul>

Analyst Color

Biotech

Earnings

Equities

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

GILD

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

Once you have been in the financial publishing industry long enough, you realize that people write a lot of what passes for content and analysis that have no idea how markets and economics work.
They know little to nothing about behavioral economics or balance sheet analysis.
They have never worked on a desk, been in a pit, dealt with a margin call, or taken panicked phone calls from investors after a market crash.
They have degrees in English, Communication, and, worst of all, Marketing.
They write about what everyone else writes about.
They care about clicks and not profits.
They can write an elegantly structured paragraph summarizing a recent PR puff piece, which is about as valuable as government peanut butter and cheese.
It fills space but does not have much value.
This becomes glaringly obvious when you read the nonsense that gets written about institutional buying and selling activities.
I regularly see articles that breathlessly announce that Vanguard has bought or sold a major portion of a company.
We also see announcements involving activity by BlackRock and Fidelity, and the articles imply that these purchases have some meaning.
They do not.
Vanguard and BlackRock are the largest purveyors of index funds. Their buying and selling may tell a story about fund flows, but the individual security activity is meaningless.
Fidelity is so big that if they look at a company, they accidentally cross the 5% ownership threshold that triggers an SEC filing.
Tracking institutional activity is valuable if you know which transactions matter and which ones do not.
Vanguard buying shares of Robinhood (Ticker: HOOD) and selling some Nikola (Ticker: NKLA does not mean anything to stock investors looking for potential bargains.
Several institutions with specialized information and vital track records buying into a beaten-up sector potentially has enormous value.
One of the most beaten-up sectors is real estate.
As all the Instant Experts on the Internet will inform you, real estate is the single worst asset class in the history of assets.
There is an excellent chance that no one will ever go into an office again.
We have so many apartments that the suburbs look like scenes from a post-apocalyptic Western, with tumbleweeds blowing through mile after mile of empty apartment buildings.
No one goes to shopping centers anymore.
Everything is delivered.
All those cars are just using the free parking spaces.
The banking system is so choked with bad real estate loans that it will collapse any day and be replaced by the newest top-secret penny crypto, which has the potential to make you a billionaire in a week starting next Tuesday.
I have heard these types of stories swirling around real estate before and during my career.
Texas real estate was a disaster in the 1980s, and you could barely give it away.
In the aftermath of the S&amp;L crisis in the 1980s and early 1990s, real estate attracted all sorts of negative attention.
It was even worse in the aftermath of the internet bubble bursting.
The Great Financial Crisis was the gold standard for toxic real estate conversations.
Each time the smart money piled in and made a fortune.
According to recent SEC filings, they are doing it again this time.
The Macquarie Group is a division of the Macquarie Bank in Sydney, Australia. The group handles the bank&#8217;s business and investing outside of Australia and has had quite a reputation over the years as a very shrewd and profitable dealmaker.
In the second half of 2024, Macquarie Group has been moving into US real estate.
The firm just filed forms with the SEC revealing it now owns over 5% of Lexington Realty Trust, an owner of single-tenant warehouse and industrial properties in Ohio, Indiana, South Carolina, Georgia, and Arizona.
The firm is clearly very bullish on the single-tenant industrial markets as it has also been buying shares of Plymouth Industrial REIT (Ticker: PLYM) this year.
The firm is also a large owner and frequent buyer of VICI Properties (Ticker: VICI), an owner of casinos with a strong presence in the Las Vegas market and an outstanding history of growing both cash flows and dividend payouts.
Robert Robotti is one of those under-the-radar value investors most people do not know exist, but since opening his doors over 40 years ago, he has crushed the markets.
Robotti recently filed paperwork with the SEC revealing that he now owns 9.7% of Five Points Holdings (Ticker: FPH), a master-planned community developer that combines residential, commercial, retail, educational, and recreational elements.
The Irvine, California, company does business in Orange County, Los Angeles County, and San Francisco County and has not been a favorite of the markets since its IPO in 2017.
Sam Levinson, the Chief Investment Officer at Glick Family Investments and member of the Five Points Board, has also been making large purchases of the stock recently.
The stock is ridiculously undervalued, with shares trading at 4.4 times free cash flow and 41% of tangible book value.
If Five Points just survives, you have a strong chance of at least doubling your money.
Robotti also accumulated shares of Legacy Homes (Ticker: LEGH), a builder of manufactured and tiny homes, earlier this year.
Smart money is moving into real estate at current prices.
For what it is worth, fund flows are even forcing indexers like Vanguard and BlackRock to buy real estate-related companies.
The Instant Experts of the Internet hate what the smart money is buying. That is an excellent buy signal in our book.

Opinion

HOOD

LEGH

PLYM

VICI

C-Suite Buys of the Week: Decoding Smart Money Moves in Real Estate

Canaccord Genuity analyst Richard Close maintains Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) with a Buy and raises the price target from $30 to $36.

Canaccord Genuity Maintains Buy on Waystar Holding, Raises Price Target to $36

Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>), a maker of branded consumer products, including alternative smoking accessories and consumables with active ingredients, announced its financial results Thursday for the third quarter ended Sept. 30, 2024.
The company behind Zig-Zag, a brand of rolling papers in the cannabis industry, said total consolidated net sales increased 3.8% year over year to $105.6 million.
Zig-Zag products&#8217; net sales, which accounted for 47% of total net sales in the quarter, increased 5.5% over the same period to $49.3 million, driven by strong performance in our North American Papers &amp; Wraps business and solid growth in cigars.
Graham Purdy, the company&#8217;s president and CEO, said Zig-Zag is on "a sustainable growth trajectory."
Zig-Zag Products segment gross profit increased 2.2% to $27.3 million. Gross margin declined 180 basis points to 55.4% driven primarily by product mix.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40108639/zig-zag-segment-on-sustainable-growth-trajectory-turning-point-ceo-reports-7-yoy-improvement-in-">Zig-Zag Segment On Sustainable Growth Trajectory, Turning Point CEO Reports 7% YoY Improvement In Adjusted EBITDA, Raises 2024 Guidance</a>
<h3 class="wp-block-heading">Other Q3 Financial Highlights</h3>
<ul>
<li>Gross profit totaled $53.7 million, up from $51.6 million in the prior year's quarter.</li>
<li>Selling, general and administrative expenses amounted to $33.2 million, compared to $31.4 million in the third quarter of last fiscal year.</li>
<li>Net loss attributable to non-controlling interest totaled $16 000, compared to net income attributable to non-controlling interest of $35 000 in the prior year's quarter.</li>
<li>Net income attributable to Turning Point Brands amounted to $12.4 million, up from $10.8 million.</li>
<li>Total gross debt as of Sept. 30, 2024 was $250 million.</li>
<li>Net debt as of Sept. 30, 2024 was $216.4 million.</li>
<li>Ended the quarter with total liquidity of $92.4 million, comprised of $33.6 million in cash and $58.8 million of asset-backed revolving credit facility capacity.</li>
</ul>
<h3 class="wp-block-heading">2024 Outlook</h3>
Turning Point increased its previous full-year 2024 adjusted EBITDA guidance from $98 million to $102 million to $101 million to $103 million, excluding CDS.
During the quarter, the company repurchased 26,978 shares of common stock for $1.1 million.
On Nov. 6, 2024, the board of directors of the company increased the company's share repurchase authorization by $77.9 million to an aggregate amount of $100 million.
Read Next:
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/05/38620478/zig-zag-rolling-paper-sales-made-48-of-total-turning-point-brands-sales-in-first-quarter">Zig-Zag Rolling Paper Sales Made 48% Of Total Turning Point Brands Sales In First Quarter</a></li>
</ul>
<h3 class="wp-block-heading">TPB Price Action</h3>
Turning Point Brands' shares traded 1.31% lower at $50.37 per share at the time of writing on Thursday.

Cannabis

Zig-Zag Rolling Papers Segment Drives 47% Of Turning Point Brands' Q3 Sales, CEO Predicts Sustainable Growth

Canaccord Genuity analyst Maria Ripps maintains Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Buy and raises the price target from $15 to $18.

UPWK

Canaccord Genuity Maintains Buy on Upwork, Raises Price Target to $18

CELU

Celularity Shares Resume Trading

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Buy and lowers the price target from $57 to $56.

TNDM

Canaccord Genuity Maintains Buy on Tandem Diabetes Care, Lowers Price Target to $56

Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) reported better-than-expected earnings for the <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5978b62d43229a0001537151/mark-miller">first quarter on Wednesday</a>.
The company posted quarterly earnings of 74 cents per share which beat the analyst consensus estimate of 61 cents per share. The company reported quarterly sales of $1.35 billion which beat the analyst consensus estimate of $1.31 billion.
Jim Anderson, CEO, said, &#8220;We delivered solid growth in the September quarter on both a sequential and year-over-year basis, driven primarily by our AI-related Datacom transceivers. We also drove higher gross margin and operating margin. I continue to be excited by the opportunity to unlock significant long-term shareholder value.&#8221;
Coherent said it sees second-quarter revenue of $1.33 billion to $1.41 billion and adjusted EPS of 61 cents to 77 cents.
Coherent shares gained 5.3% to trade at $104.72 on Thursday.
These analysts made changes to their price targets on Coherent following earnings announcement.
<ul>
<li>Benchmark analyst Mark Miller maintained Coherent with a Buy and raised the price target from $90 to $112.</li>
<li>Susquehanna analyst Mehdi Hosseini maintained Coherent with a Positive and raised the price target from $120 to $125.</li>
<li>Citigroup analyst Atif Malik maintained Coherent with a Buy and raised the price target from $88 to $106.</li>
</ul>
Considering buying COHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="476" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07134102/image-83-1024x476.png" alt="" class="wp-image-636077" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07134102/image-83-1024x476.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07134102/image-83-300x140.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07134102/image-83-768x357.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07134102/image-83.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41809435/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Markets

COHR

Coherent Analysts Boost Their Forecasts Following Better-Than-Expected Earnings

Canaccord Genuity analyst Michael Graham maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Buy and raises the price target from $18 to $22.

LYFT

Canaccord Genuity Maintains Buy on Lyft, Raises Price Target to $22

Canaccord Genuity analyst David Hynes maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Buy and raises the price target from $32 to $40.

KVYO

Canaccord Genuity Maintains Buy on Klaviyo, Raises Price Target to $40

B of A Securities analyst Michael McGovern maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Buy and raises the price target from $16 to $19.

B of A Securities Maintains Buy on Lyft, Raises Price Target to $19

JMP Securities analyst Nicholas Jones maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Market Outperform and raises the price target from $62 to $82.

JMP Securities Maintains Market Outperform on Zillow Gr, Raises Price Target to $82

Canaccord Genuity analyst Richard Davis maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $600 to $710.

HUBS

Canaccord Genuity Maintains Buy on HubSpot, Raises Price Target to $710

Canaccord Genuity analyst David Hynes maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and raises the price target from $17 to $19.

FRSH

Canaccord Genuity Maintains Buy on Freshworks, Raises Price Target to $19

B of A Securities analyst John Murphy maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Buy and raises the price target from $265 to $350.

TSLA

B of A Securities Maintains Buy on Tesla, Raises Price Target to $350

JMP Securities analyst Patrick Walravens maintains Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) with a Market Outperform and raises the price target from $47 to $61.

VERX

JMP Securities Maintains Market Outperform on Vertex, Raises Price Target to $61

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading lower on Thursday</a>. Bernstein analyst Toni Sacconaghi downgraded Ford Motor from Outperform to Market Perform, <a target="_blank" href="https://www.benzinga.com/quote/F/analyst-ratings" rel="noreferrer noopener">with a price forecast of&nbsp;$11.</a>
In an unrelated development, Ford revealed on Thursday that it is experiencing record sales growth in the Middle East in 2024, driven by strong performance in key markets and the introduction of its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41799089/fords-winning-lineup-fuels-record-sales-in-the-middle-east-sets-stage-for-electrified-future" rel="noreferrer noopener">freshest lineup to date.</a>
The launch of the Mustang Mach-E and Territory Hybrid highlights Ford&#8217;s commitment to an electrified future in the region.
Kay Hart, president of Ford&#8217;s International Markets Group, stated that the Mustang Mach-E is Ford&#8217;s first fully electric vehicle for the region and described it as one of the most exciting vehicles the company has ever produced.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-" rel="noreferrer noopener">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a>
Additionally, Ford highlighted that it is expanding its connected services offering, with the 2025 introduction of FordPass for customers in the Middle East.
&#8220;This success is due to strong market share gains by our distributors in key countries such as the&nbsp;United Arab Emirates,&nbsp;Kuwait,&nbsp;Bahrain,&nbsp;Qatar&nbsp;and&nbsp;Saudi Arabia,&#8221; said&nbsp;Ravi Ravichandran, president of Ford Middle East.
Next year, Ford will accelerate the launch of Ford Connected Services with the FordPass app first in the UAE, followed by&nbsp;Saudi Arabia.
This move further enhances Ford&#8217;s commitment to providing a better connected driving experience.
Ford is also enhancing its regional operations with the opening of a new parts distribution center in the UAE, slated for January 2025. The facility will enable faster delivery of parts to distributors, ensuring quicker service for Ford owners.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, F stock has gained over 8% in the past year. Investors can gain exposure to the stock via First Trust Nasdaq Transportation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>) and&nbsp;WBI Power Factor High Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBIY#NYSE">WBIY</a>).
Price Action: F shares are trading lower by 1.79% to $10.99 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41807254/trump-election-raises-odds-of-roaring-2020s-scenario-veteran-wall-street-investor-s" target="_blank" rel="noreferrer noopener">Trump Election Raises Odds Of &#8216;Roaring 2020s Scenario,&#8217; Veteran Wall Street Investor Says: How High Could US Stock Market Rise?</a></li>
</ul>

Downgrades

FTXR

WBIY

What's Going On With Ford Motor Stock Today?

In a report released today, Omar Dessouky from Bank of America Securities maintained a Sell rating on Cardlytics (CDLX – Research Report). The comp...

Bank of America Securities Remains a Sell on Cardlytics (CDLX)

In a report released today, Luke Horton from Northland Securities downgraded Cardlytics (CDLX – Research Report) to a Hold, with a price target of ...

Northland Securities downgrades Cardlytics (CDLX) to a Hold

Warning: CDLX is at high risk of performing badly

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Cardlytics (CDLX) has received a new Hold rating, initiated by Evercore ISI analyst, Mark Mahaney. Mark Mahaney has given his Hold rating due to a ...

Cardlytics: Balancing Strong Partnerships and ARPU Potential with Economic Sensitivity and Operational Risks

Cardlytics Non-GAAP EPS of -$0.15 beats by $0.12, revenue of $67.06M beats by $9.49M

Cardlytics, Inc. (CDLX) Q3 2024 Earnings Call Transcript

Cardlytics, Inc. ( ($CDLX) ) has released its Q3 earnings. Here is a breakdown of the information Cardlytics, Inc. presented to its investors. Card...

Cardlytics Reports Q3 2024 Financial Results

In a report released today, Jacob Stephan from Lake Street maintained a Hold rating on Cardlytics (CDLX – Research Report), with a price target of ...

Comments

Cardlytics

Cardlytics (CDLX) Opciones

Cardlytics (NASDAQ:CDLX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL